Inclusion Criteria:

- Women aged from 18 to 70 years;

- WHO Performance status (ECOG) of 0 or 1

- Core biopsy histologically proven Ⅱa-Ⅲc phase breast cancer (regardless of the type);

- Immunohistochemisty（IHC）：ER-，PR-，CerB2-；Triple negative （ER-PR-Her-2-） Hormone
receptor negativity is defined as ER<10%, PR<10% (IHC), HER2 negativity is defined as
IHC 0-1+, or [IHC 2+ and FISH or CISH negative]；

- Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x
109/l, Hemoglobin > 9 g/dl);

- Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5
ULN,total bilirubin £ 1,5 ULN;

- Adequate renal function: serum creatinine £ 1.5 ULN;

- Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography，and
electrocardiogram doe not show specific abnormality；

- Patients accepting contraception intake during the overall length of treatment if of
childbearing potential;

- Signed written informed consent.

Exclusion Criteria:

- Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast
cancer);

- ER+ or PR+ or Her-2 overexpression

- Any chemotherapy, hormonal therapy or radiotherapy before

- Previous cancer in the preceding 10 years;

- Patients already included in another therapeutic trial involving an experimental
drug;

- Patients with other concurrent severe and/or uncontrolled medical disease or
infection which could compromise participation in the study;

- LEVF < 50% (MUGA scan or echocardiography);

- Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart
failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral
vascular accidents) within 6 months prior to chemotherapy;

- Known prior severe hypersensitivity reactions to agents that will be received;

- Women who are pregnant or breastfeeding. Adequate birth control measures should be
taken during study treatment phase;

- Women with a positive pregnancy test en enrollment or prior to study drug
administration;

- Patients with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the
trial;

- Individual deprived of liberty or placed under the authority of a tutor.